Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Media Corporation Series C Liberty Formula One Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $22.59B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is far larger — about 15.6× uniQure N.V. Ordinary Shares's market cap, and Liberty Media Corporation Series C Liberty Formula One Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FWONK | QURE | |
|---|---|---|
Market Cap | $22.59B | $1.45B |
Volume | 2,257,903 | 3,323,243 |
Sector | Media | Health |
52-Week High | $106.66 | $70.59 |
52-Week Low | $81.42 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $26.05B | $707.46M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Liberty Media Corporation Series C Liberty Formula One Common Stock
Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
